Details for Patent: 8,183,274
✉ Email this page to a colleague
Which drugs does patent 8,183,274 protect, and when does it expire?
Patent 8,183,274 protects XTANDI and is included in two NDAs.
This patent has one hundred and thirty-eight patent family members in twenty-eight countries.
Summary for Patent: 8,183,274
| Title: | Treatment of hyperproliferative disorders with diarylhydantoin compounds |
| Abstract: | The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer. |
| Inventor(s): | Sawyers; Charles L. (New York, NY), Jung; Michael E. (Los Angeles, CA), Chen; Charlie D. (Shanghai, CN), Ouk; Samedy (Costa Mesa, CA), Tran; Chris (New York, NY), Wongvipat; John (Nanuet, NY) |
| Assignee: | The Regents of the University of California (Oakland, CA) |
| Application Number: | 12/708,523 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,183,274 |
|
Patent Claim Types: see list of patent claims | Use; Delivery; Formulation; Dosage form; Composition; |
Drugs Protected by US Patent 8,183,274
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL | ⤷ Try a Trial | ||||
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC). | ⤷ Try a Trial | ||||
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ⤷ Try a Trial | ||||
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) | ⤷ Try a Trial | ||||
| Astellas | XTANDI | enzalutamide | CAPSULE;ORAL | 203415-001 | Aug 31, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS | ⤷ Try a Trial | ||||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) | ⤷ Try a Trial | ||||
| Astellas | XTANDI | enzalutamide | TABLET;ORAL | 213674-001 | Aug 4, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,183,274
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E541571 | ⤷ Try a Trial | |||
| Australia | 2006248109 | ⤷ Try a Trial | |||
| Australia | 2007245022 | ⤷ Try a Trial | |||
| Brazil | PI0610359 | ⤷ Try a Trial | |||
| Brazil | PI0709682 | ⤷ Try a Trial | |||
| Canada | 2608436 | ⤷ Try a Trial | |||
| Canada | 2648139 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
